Oscar Health Inc (OSCR)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $9.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
Oscar Health Inc (OSCR) Stock Forecast
Analysts expect Oscar Health (OSCR) to earn $2.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $19.06B. Of 11 analysts, 3 rate the stock Buy or Strong Buy, 7 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.64, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 27% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 27.3% |
| Buy | 0 | 0.0% |
| Hold | 7 | 63.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 9.1% |
- Consensus
- Hold
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 3.4% and revenue estimates rise 10.7%.
- Fiscal year ending Dec 31, 2026
- $2.37
- EPS consensus, revenue $19.06B
- Fiscal year ending Dec 31, 2027
- $2.45
- EPS consensus, revenue $21.09B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.37 | $1.84 to $2.70 | 7 | $19.06B | $18.75B to $19.25B | 9 |
| Dec 31, 2027 | $2.45 | $2.00 to $3.08 | 8 | $21.09B | $16.81B to $23.01B | 10 |
Quarterly Estimates
The EPS consensus rises from -$1.12 for the quarter ending Dec 31, 2026 to $2.27 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.12 | -$1.21 to -$1.03 | 14 | $4.61B | $4.39B to $4.81B | 12 |
| Mar 31, 2027 | $2.27 | $1.81 to $2.76 | 4 | $5.52B | $5.04B to $5.85B | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 39.4% from $1.70.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.37 | $1.94 | $1.91 | $1.75 | $1.70 | +40.0% |
| Fiscal year ending Dec 31, 2027 | $2.45 | $2.22 | $2.17 | $1.88 | $1.75 | +39.9% |
| Quarter ending Mar 31, 2027 | $2.27 | $2.25 | $2.21 | $2.21 | $2.21 | +2.3% |
Frequently Asked Questions About OSCR
What is the OSCR stock forecast?
Consensus analyst estimates put Oscar Health's EPS at $2.37 for the fiscal year ending Dec 31, 2026, on revenue of $19.06B. The consensus rating from 11 analysts is Hold.
How do analysts rate OSCR stock?
Of 11 analysts covering Oscar Health, 3 rate it Strong Buy, 0 Buy, 7 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from OSCR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.37, with estimates from $1.84 to $2.70 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.45, with estimates from $2.00 to $3.08 from 8 analysts.
What revenue do analysts expect from Oscar Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $19.06B, with estimates from $18.75B to $19.25B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $21.09B, with estimates from $16.81B to $23.01B.
How many analysts cover OSCR?
11 analysts rate Oscar Health stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OSCR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors